In this study, patients with surgery of both brain and lung lesions followed by EGFR-TKIs had prolonged survival, which supported that EGFR-TKIs are recommended as adjuvant treatment of EGFR mutated NSCLC patients with solitary BM. This evidence concerns the gene EGFR and non-small cell lung carcinoma.